Overview

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Status:
Completed
Trial end date:
2007-05-29
Target enrollment:
0
Participant gender:
All
Summary
An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UCB Pharma
UCB Pharma SA
Treatments:
Etiracetam
Levetiracetam
Piracetam
Criteria
Inclusion Criteria:

- Subjects with a confirmed diagnosis of epilepsy.

- Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with
clear focal origin),or generalized tonic-clonic seizures (without clear focal origin),
that are classifiable according to the International Classification of Epileptic
Seizures

- Subjects having participated in the previous double-blind monotherapy trial (N01061
[NCT00150735] or N01093 [NCT00150787]).

- Male/female subjects (>= 16 years).

Exclusion Criteria:

- Need for an additional Antiepileptic Drug (AED).